HomeBLUE • NASDAQ
bluebird bio Inc
$1.37
Pre-market:
$1.35
(1.12%)-0.015
Closed: Mar 28, 8:45:00 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$1.37
Year range
$0.88 - $5.53
Market cap
259.84M USD
Avg Volume
10.01M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Sep 2023Y/Y change
Revenue
12.39M17,353.52%
Operating expense
84.10M3.43%
Net income
-71.73M6.26%
Net profit margin
-578.8599.46%
Earnings per share
-0.6631.19%
EBITDA
-83.66M1.69%
Effective tax rate
Total assets
Total liabilities
(USD)Sep 2023Y/Y change
Cash and short-term investments
174.29M24.82%
Total assets
613.61M17.98%
Total liabilities
391.07M8.26%
Total equity
222.54M
Shares outstanding
109.34M
Price to book
0.66
Return on assets
-33.17%
Return on capital
-37.75%
Net change in cash
(USD)Sep 2023Y/Y change
Net income
-71.73M6.26%
Cash from operations
-61.85M19.71%
Cash from investing
62.08M297.74%
Cash from financing
-42.00K-100.09%
Net change in cash
195.00K101.29%
Free cash flow
-59.31M-23.44%
About
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union - approved drug is betibeglogene autotemcel, which treats transfusion-dependent beta thalassemia, a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world. The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors. Wikipedia
Founded
Apr 16, 1992
Employees
323
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu